254 related articles for article (PubMed ID: 25053163)
21. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency.
Schroers A; Kley RA; Stachon A; Horvath R; Lochmüller H; Zange J; Vorgerd M
Neurology; 2006 Jan; 66(2):285-6. PubMed ID: 16434679
[No Abstract] [Full Text] [Related]
22. Systemic AAV8-mediated delivery of a functional copy of muscle glycogen phosphorylase (Pygm) ameliorates disease in a murine model of McArdle disease.
McNamara EL; Taylor RL; Clayton JS; Goullee H; Dilworth KL; Pinós T; Brull A; Alexander IE; Lisowski L; Ravenscroft G; Laing NG; Nowak KJ
Hum Mol Genet; 2020 Jan; 29(1):20-30. PubMed ID: 31511858
[TBL] [Abstract][Full Text] [Related]
23. McArdle Disease: Update of Reported Mutations and Polymorphisms in the PYGM Gene.
Nogales-Gadea G; Brull A; Santalla A; Andreu AL; Arenas J; Martín MA; Lucia A; de Luna N; Pinós T
Hum Mutat; 2015 Jul; 36(7):669-78. PubMed ID: 25914343
[TBL] [Abstract][Full Text] [Related]
24. Absence of p.R50X
Tarrasó G; Real-Martinez A; Parés M; Romero-Cortadellas L; Puigros L; Moya L; de Luna N; Brull A; Martín MA; Arenas J; Lucia A; Andreu AL; Barquinero J; Vissing J; Krag TO; Pinós T
Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31848135
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel PYGM mutation in a McArdle disease patient misdiagnosed as hypokalemic periodic paralysis.
Xie RR; Yang YB; Jin P
J Endocrinol Invest; 2020 May; 43(5):697-698. PubMed ID: 32100198
[No Abstract] [Full Text] [Related]
26. The effect of muscle glycogen phosphorylase (Pygm) knockdown on zebrafish morphology.
Migocka-Patrzałek M; Lewicka A; Elias M; Daczewska M
Int J Biochem Cell Biol; 2020 Jan; 118():105658. PubMed ID: 31747538
[TBL] [Abstract][Full Text] [Related]
27. Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model.
Brull A; de Luna N; Blanco-Grau A; Lucia A; Martin MA; Arenas J; Martí R; Andreu AL; Pinós T
J Physiol; 2015 Jun; 593(12):2693-706. PubMed ID: 25873271
[TBL] [Abstract][Full Text] [Related]
28. Six novel mutations in the myophosphorylase gene in patients with McArdle disease and a family with pseudo-dominant inheritance pattern.
Wu Y; Weber JL; Vladutiu GD; Tarnopolsky MA
Mol Genet Metab; 2011 Dec; 104(4):587-91. PubMed ID: 21880526
[TBL] [Abstract][Full Text] [Related]
29. Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins.
Núñez-Manchón J; Ballester-Lopez A; Koehorst E; Linares-Pardo I; Coenen D; Ara I; Rodriguez-Lopez C; Ramos-Fransi A; Martínez-Piñeiro A; Lucente G; Almendrote M; Coll-Cantí J; Pintos-Morell G; Santos-Lozano A; Arenas J; Martín MA; de Castro M; Lucia A; Santalla A; Nogales-Gadea G
J Inherit Metab Dis; 2018 Nov; 41(6):1027-1035. PubMed ID: 29926259
[TBL] [Abstract][Full Text] [Related]
30. PYGM expression analysis in white blood cells: a complementary tool for diagnosing McArdle disease?
de Luna N; Brull A; Lucia A; Santalla A; Garatachea N; Martí R; Andreu AL; Pinós T
Neuromuscul Disord; 2014 Dec; 24(12):1079-86. PubMed ID: 25240406
[TBL] [Abstract][Full Text] [Related]
31. Expression of glycogen phosphorylase isoforms in cultured muscle from patients with McArdle's disease carrying the p.R771PfsX33 PYGM mutation.
Nogales-Gadea G; Mormeneo E; García-Consuegra I; Rubio JC; Orozco A; Arenas J; Martín MA; Lucia A; Gómez-Foix AM; Martí R; Andreu AL
PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957198
[TBL] [Abstract][Full Text] [Related]
32. Expression of the muscle glycogen phosphorylase gene in patients with McArdle disease: the role of nonsense-mediated mRNA decay.
Nogales-Gadea G; Rubio JC; Fernandez-Cadenas I; Garcia-Consuegra I; Lucia A; Cabello A; Garcia-Arumi E; Arenas J; Andreu AL; Martín MA
Hum Mutat; 2008 Feb; 29(2):277-83. PubMed ID: 17994553
[TBL] [Abstract][Full Text] [Related]
33. High-resolution melting facilitates mutation screening of PYGM in patients with McArdle disease.
Duno M; Quinlivan R; Vissing J; Schwartz M
Ann Hum Genet; 2009 May; 73(Pt 3):292-7. PubMed ID: 19472443
[TBL] [Abstract][Full Text] [Related]
34. A new rare mutation (691delCC/insAAA) in exon 17 of the PYGM gene causing McArdle disease.
Quintans B; Sanchez-Andrade A; Teijeira S; Fernandez-Hojas R; Rivas E; López MJ; Navarro C
Arch Neurol; 2004 Jul; 61(7):1108-10. PubMed ID: 15262743
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and genetic analysis of a case with glycogen storage disease type V caused by compound heterozygous mutations in the PYGM gene.
Jiang WZ; Xu YW; Wang YW; Zhu XC; Gong YY; Zhou HW; Fu ZZ
Yi Chuan; 2022 Nov; 44(11):1063-1071. PubMed ID: 36384998
[TBL] [Abstract][Full Text] [Related]
36. McArdle disease: the mutation spectrum of PYGM in a large Italian cohort.
Bruno C; Cassandrini D; Martinuzzi A; Toscano A; Moggio M; Morandi L; Servidei S; Mongini T; Angelini C; Musumeci O; Comi GP; Lamperti C; Filosto M; Zara F; Minetti C
Hum Mutat; 2006 Jul; 27(7):718. PubMed ID: 16786513
[TBL] [Abstract][Full Text] [Related]
37. A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients.
Rubio JC; Garcia-Consuegra I; Nogales-Gadea G; Blazquez A; Cabello A; Lucia A; Andreu AL; Arenas J; Martin MA
Hum Mutat; 2007 Feb; 28(2):203-4. PubMed ID: 17221871
[TBL] [Abstract][Full Text] [Related]
38. Novel human pathological mutations. Gene symbol: PYGM. Disease: McArdle disease.
Viéitez I; Teijeira S; Miranda S; San Millán B; Navarro C
Hum Genet; 2010 Jan; 127(1):114-5. PubMed ID: 20108426
[No Abstract] [Full Text] [Related]
39. Clinical and laboratory features of patients with myophosphorylase deficiency (McArdle disease).
Miteff F; Potter HC; Allen J; Teoh H; Roxburgh R; Hutchinson DO
J Clin Neurosci; 2011 Aug; 18(8):1055-8. PubMed ID: 21658951
[TBL] [Abstract][Full Text] [Related]
40. McArdle Disease: New Insights into Its Underlying Molecular Mechanisms.
Llavero F; Arrazola Sastre A; Luque Montoro M; Gálvez P; Lacerda HM; Parada LA; Zugaza JL
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
